Tradestie Institutional Equity Comparison Engine

CGEM vs MPLT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CGEM Overall Edge

CGEM Captures Institutional Edge (3โ€“1 Pillars ยท 5โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cullinan Therapeutics, Inc. Common Stock (CGEM) driven by superior Valuation, Growth & Margin, Momentum & Technical while MPLT counters with relative strength in Options & Structure. Fundamentally, CGEM trades at 6.7x Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus MPLT at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, CGEM sits in UNCLASSIFIED (9th %ile IV; Dealer Gamma Walls on Pro) against MPLT sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CGEM
CGEM 6.7x vs MPLT N/M Fwd P/E
Growth & Margin Winner CGEM
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner CGEM
1Y +17.5% vs -51.4% ยท 52W Pos 12% vs 3%
Options & Structure Winner MPLT
UNCLASSIFIED (9th %ile IV) vs BREAKDOWN (8th %ile IV)
CGEM NASDAQ
Cullinan Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.72
-5.45% 1D
Market Cap $653.8M
1M Return -24.83%
1Y Return +17.53%
Forward P/E 6.7x
Unified AI Score
48.4 / 100 HOLD
Tech 45.0 Fund 51.0 Flow 50.0 Mom 59.0
MPLT US Equity
MapLight Therapeutics, Inc.
Pharmaceutical Preparations
$6.94
-4.28% 1D
Market Cap $392.9M
1M Return -9.87%
1Y Return -51.4%
Forward P/E N/M
Unified AI Score
50.4 / 100 HOLD
Tech 49.0 Fund 56.0 Flow 64.0 Mom 58.9

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CGEM +17.53% MPLT -51.4% Spread: +68.93 pp (CGEM Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CGEM TTM Op. Margin: 0.0% MPLT TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CGEM vs MPLT. Trailing 12-month operating profitability (CGEM 0.0% vs MPLT 0.0%) and valuation multiples (CGEM 6.7x vs MPLT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CGEM (5) vs MPLT (2)
Institutional Metric CGEM MPLT Criterion Row Winner
Market Capitalization Scale $653.8M $392.9M Larger Scale CGEM
Trailing P/E Ratio Valuation 6.7x N/M Lower Multiple CGEM
Forward P/E Ratio Valuation 6.7x N/M Lower Multiple CGEM
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -50.3% -111.5% Higher ROE CGEM
52-Week Range Position Momentum 12% ($8โ€“$23) 3% ($6โ€“$40) Stronger Trend CGEM
Beta / 30D Volatility Risk Regime 1.56ฮฒ ยท 104% Vol 1.05ฮฒ ยท 78% Vol Lower Realized Risk MPLT
Unified Institutional Score Composite Signal 48.4 / 100 (HOLD) 50.4 / 100 (HOLD) Higher Composite MPLT

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CGEM vs MPLT Buy Guide
CGEM UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 9th %ile
IV Regime Compressed (<25th %ile)
Live CGEM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MPLT BREAKDOWN
144d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 8th %ile
IV Regime Compressed (<25th %ile)
Live MPLT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CGEM nor MPLT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.